CINCINNATI, OH--(Marketwire - March 22, 2011) -
Medpace, Inc. today announced the addition of Brian S. Murphy, MD, MPH as Medical Director with responsibility for leading clinical drug development for infectious disease and pediatric specific agents. The addition of Dr. Murphy, along with existing clinical and medical teams, will allow Medpace to provide deeper expertise in emerging therapeutic areas
to bring innovative anti-infective and pediatric drugs to market in partnership with our sponsors.
"Dr. Murphy's reputation as an academic leader, combined with his years of experience in clinical development makes him a perfect fit for Medpace," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "He will contribute to Medpace's entry into one of the major therapeutic areas that poses challenges for emerging markets, that of infectious disease and the need for new and effective vaccines."
Dr. Brian Murphy brings to the Medpace medical management team over ten years of work at the University of Kentucky where he most recently served as Assistant Professor in the Division of Infectious Disease, the Department of Pediatrics, and the Department of Microbiology, Immunology, and Molecular Genetics. He has worked with multi-disciplinary translational/clinical research teams as the principal investigator and consultant on multiple funded projects investigating the pathogenesis and management of HIV, pulmonary infections, infections affecting immunocompromised patients and patients with chronic lung diseases i.e., cystic fibrosis and chronic obstructive pulmonary disease, fungal diseases, vaccine development, bioterrorism, and immunotherapeutics.
Dr. Murphy received his Doctor of Medicine degree from the University of Louisville and his undergraduate diploma in biology from the University of Louisville. Dr Murphy also received his Master of Public Heath in Epidemiology from the University of Kentucky.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com